{"ATC Code":"N04BD02","Abbreviation":[],"Actives":["(R)-1-Aminoindan"],"Aliases":["N-2-Propynyl-1-indanamine","TV-1030","Rasagilina","(1R)-N-propargylindan-1-amine","Indan-1-yl-prop-2-ynyl-amine","Agn-1135","1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-,","rasagilinum","TVP-101","N04BD02","851-611-1","N-2-propynyl-1-indanamine","TVP-1022","TVP1022","N-(2-Propynyl)-2,3-dihydroinden-1-amine","(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine","1-Indanamine, N-2-propynyl-","Azilect","RAS","1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)-","2,3-dihydro-N-2-propynyl-1H-inden-1-amine","N-(Prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine","(+)-Rasagiline","(1R)-N-prop-2-ynylindan-1-amine","TV 1030"],"Biological Half-Life":"Rasagiline has a mean steady-state half life of 3 hours but there is no correlation of pharmacokinetics with its pharmacological effect because of its irreversible inhibition of MAO-B.","CAS":"136236-51-6","ChEBI":"CHEBI:63620","ChEMBL":"CHEMBL887","ChemicalClasses":["aminoindane"],"Chirality":"achiral","Classes":["Monoamine oxidase inhibitor","Prodrug"],"Drug Classes":"Breast Feeding; Lactation; Antiparkinson Agents; Monoamine Oxidase Inhibitors; Neuroprotective Agents","Drug Indication":"For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.","Drug Warnings":"When used as monotherapy, postural hypotension was reported in approximately 3% of patients treated with 1 mg rasagiline and 5% of patients treated with placebo. In the monotherapy trial, postural hypotension did not lead to drug discontinuation and premature withdrawal in the rasagiline or placebo treated patients. When used as an adjunct to levodopa, postural hypotension was reported in approximately 6% of patients treated with 0.5 mg rasagiline, 9% of patients treated with 1 mg rasagiline and 3% of patients treated with placebo. Postural hypotension led to drug discontinuation and premature withdrawal from clinical trials in one (0.7%) patient treated with rasagiline 1 mg/day, no patients treated with rasagiline 0.5 mg/day and no placebo-treated patients. Clinical trial data suggest that postural hypotension occurs most frequently in the first two months of rasagiline treatment and tends to decrease over time.","Erowid Experience Reports":[],"Esters":[],"European Community (EC) Number":"851-611-1","FDA Pharmacological Classification":"003N66TS6T","Formating":[],"HMDB ID":"HMDB0015454","HeavyAtomCount":13,"Human Drugs":"Breast Feeding; Lactation; Antiparkinson Agents; Monoamine Oxidase Inhibitors; Neuroprotective Agents","IUPACName":"(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine","InChI":"InChI=1S/C12H13N/c1-2-9-13-12-8-7-10-5-3-4-6-11(10)12/h1,3-6,12-13H,7-9H2/t12-/m1/s1","InChIKey":"RUOKEQAAGRXIBM-GFCCVEGCSA-N","MeSH Pharmacological Classification":"A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman\u0026apos;s The Pharmacological Basis of Therapeutics, 8th ed, p414) (See all compounds classified as Monoamine Oxidase Inhibitors.)","MolecularFormula":"C\u003csub\u003e12\u003c/sub\u003eH\u003csub\u003e13\u003c/sub\u003eN","MolecularWeight":"171.24 g/mol","Pharmacodynamics":"Rasagiline is a propargylamine and an irreversible inhibitor of monoamine oxidase (MAO). MAO, a flavin-containing enzyme, regulates the metabolic degradation of catecholamines and serotonin in the CNS and peripheral tissues. It is classified into two major molecular species, A and B, and is localized in mitochondrial membranes throughout the body in nerve terminals, brain, liver and intestinal mucosa. MAO-A is found predominantly in the GI tract and liver, and regulates the metabolic degradation of circulating catecholamines and dietary amines. MAO-B is the major form in the human brain and is responsible for the regulation of the metabolic degradation of dopamine and phenylethylamine. In ex vivo animal studies in brain, liver and intestinal tissues rasagiline was shown to be a potent,selective, and irreversible monoamine oxidase type B (MAO-B) inhibitor. At the recommended therapeutic doses, Rasagiline was also shown to be a potent and irreversible inhibitor of MAO-B in platelets. The selectivity of rasagiline for inhibiting only MAO-B (and not MAO-A) in humans and the sensitivity to tyramine during rasagiline treatment at any dose has not been sufficiently characterized to avoid restriction of dietary tyramine and amines contained in medications.","Physical Description":"Solid","PubChemId":3052776,"RefCount":2,"RefCur":"","References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Rasagiline","Name":"Rasagiline","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01367","Name":"Rasagiline","Sub":false},{"Link":"https://go.drugbank.com/drugs/DB03894","Name":"(S)-Rasagiline","Sub":true}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3052776","Name":"Rasagiline","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5289310","Name":"(S)-Rasagiline","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL887","Name":"Rasagiline","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1235738","Name":"(S)-Rasagiline","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63620","Name":"Rasagiline","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=136236-51-6","Name":"Rasagiline","Sub":false},{"Link":"https://commonchemistry.cas.org/detail?cas_rn=185517-74-2","Name":"(S)-Rasagiline","Sub":true}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0015454","Name":"Rasagiline","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D08469","Name":"Rasagiline","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/003N66TS6T","Name":"Rasagiline","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/4KM7HJ6CBA","Name":"(S)-Rasagiline","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID3041112","Name":"Rasagiline","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID001232866","Name":"(S)-Rasagiline","Sub":true}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 3052776, Rasagiline. Accessed July 27, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/3052776\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/3052776\u003c/a\u003e"],"SMILES":"C#CCN[C@@H]1CCC2=CC=CC=C12","SaltData":[],"Salts":[],"Solubility":"2.49e-02 g/L","StereoisomerData":[{"Aliases":["N-propargyl-1(s)-aminoindan","(1S)-2,3-Dihydro-N-2-propyn-1-yl-1H-inden-1-amine","(S)-N-(2-Propynyl)-2,3-dihydroinden-1-amine","S-PAI","Tvp1022;s-pai","Rasagiline S-isomer","Rasagiline, (S)-","N-propargyl-1-(s)aminoindan","orb1708290","(S)-N-2-propynyl-1-indanamine","1H-Inden-1-amine, 2,3-dihydro-N-2-propyn-1-yl-, (1S)-","HMS6018I13","(1S)-N-prop-2-ynylindan-1-amine","DB03894","AS-32581","HY-14200","Tvp1022, \u003e=98%","Q27094763","(1S)-N-prop-2-yn-1-yl-2,3-dihydro-1H-inden-1-amine","(1S)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine"],"PubChemId":5289310,"SMILES":"C#CCN[C@H]1CCC2=CC=CC=C12","Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 74.395 76.945\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h75v77H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m71.075 1.758-4.727 14.488M73.394 2.514l-4.728 14.488M68.757 1.001 64.03 15.49\"/\u003e\u003c/g\u003e\u003cpath d=\"m66.348 16.246-4.727 14.488M61.621 30.734l-11.6 2.451\" class=\"bond\"/\u003e\u003cpath fill=\"#000\" stroke=\"none\" d=\"m41.65 48.264.666.217 4.723-10.306-1.562-.51-1.563-.509z\" class=\"bond\"/\u003e\u003cpath d=\"m41.983 48.373 8.941 12.293M50.924 60.666 41.983 72.96M41.983 72.96l-14.529-4.674\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 75.906 13.208-7.62M14.246 73.091l10.77-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.246 75.906-13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M1.038 53.046v15.24M3.477 54.455v12.423\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 53.046 13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.454 53.046-13.208-7.62M25.016 54.455l-10.77-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m41.983 48.373-14.529 4.673M27.454 68.286v-15.24\" class=\"bond\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M48.651 36.334h-.72l-2.62-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482v-2.768h.578zM44.208 36.334h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.072h2.513v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#3050f8\" d=\"m50.021 33.185 5.8-1.225M50.021 33.185l5.8-1.225\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Title":"(S)-Rasagiline","UNII":"4KM7HJ6CBA"}],"Stereoisomers":["(S)-Rasagiline","(R)-Rasagiline"],"Structure":"\u003csvg xmlns=\"http://www.w3.org/2000/svg\" preserveAspectRatio=\"none\" style=\"display:block\" viewBox=\"0 0 74.395 76.945\"\u003e\u003crect width=\"100%\" height=\"100%\" fill=\"#fff\"/\u003e\u003cdesc\u003eGenerated by the Chemistry Development Kit (http://github.com/cdk)\u003c/desc\u003e\u003cg fill=\"#3050f8\" stroke=\"#000\" stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\".7\"\u003e\u003cpath fill=\"#fff\" stroke=\"none\" d=\"M0 0h75v77H0z\"/\u003e\u003cg class=\"mol\"\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m71.075 1.758-4.727 14.488M73.394 2.514l-4.728 14.488M68.757 1.001 64.03 15.49\"/\u003e\u003c/g\u003e\u003cpath d=\"m66.348 16.246-4.727 14.488M61.621 30.734l-11.6 2.451\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m41.65 48.264.666.217\"/\u003e\u003cpath stroke=\"#3050f8\" d=\"m42.161 45.759 1.22.398M42.671 43.254l1.775.579M43.182 40.749l2.329.76M43.692 38.244l2.884.941\"/\u003e\u003c/g\u003e\u003cpath d=\"m41.983 48.373 8.941 12.293M50.924 60.666 41.983 72.96M41.983 72.96l-14.529-4.674\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m14.246 75.906 13.208-7.62M14.246 73.091l10.77-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m14.246 75.906-13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"M1.038 53.046v15.24M3.477 54.455v12.423\"/\u003e\u003c/g\u003e\u003cpath d=\"m1.038 53.046 13.208-7.62\" class=\"bond\"/\u003e\u003cg class=\"bond\"\u003e\u003cpath d=\"m27.454 53.046-13.208-7.62M25.016 54.455l-10.77-6.213\"/\u003e\u003c/g\u003e\u003cpath d=\"m41.983 48.373-14.529 4.673M27.454 68.286v-15.24\" class=\"bond\"/\u003e\u003cg stroke=\"none\" class=\"atom\"\u003e\u003cpath d=\"M48.651 36.334h-.72l-2.62-4.066h-.03l.03.596q.024.357.024.732v2.738h-.566v-4.899h.715l2.607 4.054h.03l-.018-.327-.024-.477q-.006-.262-.006-.482v-2.768h.578zM44.208 36.334h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.072h2.513v-2.072h.619z\"/\u003e\u003c/g\u003e\u003cpath stroke=\"#3050f8\" d=\"m50.021 33.185 5.8-1.225M50.021 33.185l5.8-1.225\" class=\"hi\"/\u003e\u003c/g\u003e\u003c/g\u003e\u003c/svg\u003e","Subjective Effects":null,"Therapeutic Uses":"Rasagiline is used as initial monotherapy or as adjunctive therapy to levodopa for the symptomatic treatment of idiopathic parkinsonian syndrome.","Title":"Rasagiline","UNII":"003N66TS6T","Wikipedia":"Rasagiline","XLogP":1.8}